Trial Profile
A Phase I Study of Durvalumab (MEDI4736) Plus Tremelimumab in Combination With Platinum-based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer and Performance Status 2
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions
- 24 Feb 2022 Status changed from recruiting to discontinued due to low accrual.
- 15 Jul 2020 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
- 15 Jul 2020 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2021.